Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Medicare seeks public comments as the agency plans to list up to 15 additional drugs selected for the third round of pricing ...

A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

A leading obesity doctor has said a new trial of weight loss drugs Mounjaro and Wegovy may lead advertisers to reconsider their prices.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...